Cerecor’s (CERC) Buy Rating Reiterated at HC Wainwright

cerecor8217s-cerc-buy-rating-reiterated-at-hc-wainwright.jpg

Cerecor Inc (NASDAQ:CERC)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Sunday. They presently have a $15.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 289.61% from the company’s previous close.
Cerecor (NASDAQ:CERC) opened at 3.85 on Friday. The firm’s market cap is $33.30 million. Cerecor has a 52-week low of $1.94 and a 52-week high of $6.65. The firm’s 50-day moving average price is $3.79 and its 200-day moving average price is $3.33.
Cerecor (NASDAQ:CERC) last announced its quarterly earnings results on Monday, August 15th. The company reported ($0.41) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.15. Equities research analysts expect that Cerecor will post ($1.97) EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/11/cerecors-cerc-buy-rating-reiterated-at-hc-wainwright.html

About Cerecor
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

Receive News & Ratings for Cerecor Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cerecor Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Cerecor’s (CERC) Buy Rating Reiterated at HC Wainwright"

Leave a comment

Your email address will not be published.


*